# OnCo record kupando (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kupando/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kupando" ;
  schema:name "Kupando"@en ;
  schema:alternateName "Kupando GmbH"@en ;
  schema:description "Kupando develops KUP101, a medicine that switches on the body's first-line immune defences to help it attack tumours. It is in an early trial in advanced skin cancers."@en ;
  schema:url <https://onco.cc/companies/kupando/>, <https://www.kupando.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.kupando.com/>, <https://www.kupando.com/kupando-secures-additional-e10-million/>, <https://www.kupando.com/kupando-announces-first-patient-dosed-in-phase-1-clinical-study-of-lead-candidate-kup101-in-advanced-solid-tumors/>, <https://clinicaltrials.gov/study/NCT07600476> ;
  schema:addressCountry "DE" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/mucosal-melanoma/>, <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/basal-cell-carcinoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/trained-innate-immunity/> ;
  onco:targets <https://onco.cc/targets/tlr7/> .